… European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Access based … that demonstrated meaningful improvements in vision with sepofarsen,” stated Daniel A. de Boer, CEO of ProQR. “Looking …
… ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 LEIDEN, The Netherlands and CAMBRIDGE, … dosed in the Phase 2/3 ILLUMINATE clinical trial for sepofarsen (formerly named QR-110) in patients with Leber’s …
… Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Divestment of sepofarsen and ultevursen completed – Théa to continue …
… Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 LEIDEN, Netherlands & … from the U.S. Food and Drug Administration (FDA) for sepofarsen for the treatment of Leber’s congenital amaurosis …
… européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 … européenne représentera un marché important pour le Sepofarsen LEIDEN, Pays-Bas et CAMBRIDGE, Mass., 29 juill. … que son médicament-candidat en cours de développement, le Sepofarsen (QR-110), destiné à cibler la mutation p.Cys998X …
… to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO LEIDEN, the … and discuss top-line results from the Phase 1/2 study of sepofarsen on October 10, ahead of the American Academy of …
… premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10 Des … être le seul essai d'enregistrement pour le programme sepofarsen. Nous apprécions le soutien sans faille des …
… with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 … pivotal trial (“ILLUMINATE”) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 …